Android app Apple app link

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

By Yahoo! Finance   |   1 month ago
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

H.C. Wainwright analyst Yi Chen reaffirmed a Buy rating on Tourmaline Bio, Inc. and maintained a price target of $50 after positive results from the Phase 2 TRANQUILITY trial of Pacibekitug.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.